| ID | 1127 |
| Name of the vaccine | TRUMENBA |
| Microbe | Bacteria |
| Disease name | Meningococcal disease |
| Name of bacteria | Neisseria meningitidis |
| Type of vaccine | Recombinant |
| Nucleic acid content | DNA |
| Age | 10 to 25 years |
| Description of the vaccine | Meningococcal group B vaccine. |
| Name of the manufacturer | Pfizer (Wyeth Pharmaceuticals) |
| Name of the manufacturing country | Philadelphia |
| Year of manufacture | 2014 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-negative diplococcus. |
| Efficacy | Was assessed by measuring serum bactericidal activity using human complement (hSBA). |
| Vaccine formulation | Suspension in 0.5 mL single-dose prefilled syringe. |
| Dosage | Three-dose schedule: 0.5 mL at 0, 1-2, and 6 months.
Two-dose schedule: 0.5 mL at 0 and 6 months. If the second dose is given earlier than 6 months , a third dose should be given at least 4 months after the
second dose. |
| Mechanism of action | Complement-mediated antibody dependent killing of N. meningitidis. |
| Route of administration | Intramuscular |
| Indications | Prevents invasive disease caused by Neisseria meningitidis serogroup B. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Pain at the injection site, fatigue, headache and muscle pain. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/89936/download |
| Other name | NA |
| Additional Links | NA
|